The aim of our study was to clarify the emergence status in both regimens by investigating uniformly managed neuroanesthesia cases.

The anesthesia database at Yamagata University Hospital covering the period 2002-2005 was retrospectively investigated for adult patients who underwent craniotomy for primary brain selleck chemical tumor excision. General anesthesia was provided by an isoflurane- (ISO group) or propofol-based (PROP group) regimen. Times to extubation and

operating room (OR) discharge, perioperative consciousness levels, and perioperative variables were compared.

Of the 202 surgeries performed during the study period, 77 and 82 patients were anesthetized with isoflurane and propofol, respectively. Demographic data were comparable between the two groups, although the American Society of Anesthesiology grade was worse in the ACY-738 PROP group. Extubation

times [39.5 +/- A 14.6 min (ISO) vs. 29.5 +/- A 14.9 min (PROP); P < 0.001] and OR discharge times [67.2 +/- A 18.0 (ISO) vs. 53.9 +/- A 17.6 min (PROP); P < 0.001] were significantly shorter in the PROP, with significantly better immediate consciousness levels. The differences in levels of consciousness persisted for several hours postoperatively. PROP patients had significantly higher urine outputs and lower body temperatures during anesthesia. The incidences of shivering, nausea, vomiting, and convulsions were not significantly different between the groups. The time to discharge was similar between the groups.

Propofol was associated with a better recovery profile and neurological condition than isoflurane, as indicated by shorter extubation

and OR discharge times and better postoperative consciousness.”
“Objective: Therapeutic hypothermia, also known as targeted temperature management (TTM), improves clinical outcomes in patients resuscitated from cardiac arrest. Hyperthermia after discontinuation of active temperature management (“”rebound pyrexia”") has been observed, 3-MA mouse but its incidence and association with clinical outcomes is poorly described. We hypothesized that rebound pyrexia is common after rewarming in post-arrest patients and is associated with poor neurologic outcomes.

Methods: Retrospective multicenter US clinical registry study of post-cardiac arrest patients treated with TTM at 11 hospitals between 5/2005 and 10/2011. We assessed the incidence of rebound pyrexia (defined as temperature >38 degrees C) in post-arrest patients treated with TTM and subsequent clinical outcomes of survival to discharge and “”good”" neurologic outcome at discharge, defined as cerebral performance category (CPC) 1-2.

Results: In this cohort of 236 post-arrest patients treated with TTM, mean age was 58.1 +/- 15.7 y and 106/236 (45%) were female. Of patients who survived at least 24 h after TTM discontinuation (n = 167), post-rewarming pyrexia occurred in 69/167 (41%), with a median maximum temperature of 38.7 (IQR 38.3-38.9).